NASDAQ:AUPH

Aurinia Pharmaceuticals Stock Forecast, Price & News

$13.40
+0.40 (+3.08 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.76
$13.50
50-Day Range
$10.00
$14.52
52-Week Range
$9.72
$20.50
Volume3.05 million shs
Average Volume4.21 million shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.58
30 days | 90 days | 365 days | Advanced Chart
Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Aurinia Pharmaceuticals logo

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

230th out of 2,105 stocks

Pharmaceutical Preparations Industry

112th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

Is Aurinia Pharmaceuticals a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aurinia Pharmaceuticals stock.
View analyst ratings for Aurinia Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Aurinia Pharmaceuticals?

Wall Street analysts have given Aurinia Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aurinia Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in May. As of May 28th, there was short interest totaling 12,830,000 shares, an increase of 27.4% from the May 13th total of 10,070,000 shares. Based on an average trading volume of 3,620,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 11.5% of the company's shares are sold short.
View Aurinia Pharmaceuticals' Short Interest
.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Aurinia Pharmaceuticals
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted its quarterly earnings results on Wednesday, May, 5th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.05. The biotechnology company earned $0.91 million during the quarter, compared to analysts' expectations of $2.30 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 34.48% and a negative net margin of 239.29%.
View Aurinia Pharmaceuticals' earnings history
.

How has Aurinia Pharmaceuticals' stock price been impacted by COVID-19?

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AUPH shares have decreased by 5.0% and is now trading at $13.40.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AUPH?

6 brokerages have issued 1 year price objectives for Aurinia Pharmaceuticals' shares. Their forecasts range from $23.00 to $35.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $29.60 in the next year. This suggests a possible upside of 120.9% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:
  • Mr. Peter S. Greenleaf M.B.A., Pres, CEO & Director (Age 51, Pay $1.39M)
  • Mr. Joseph M. Miller C.P.A., Chief Financial Officer (Age 47, Pay $614.27k)
  • Mr. Matthew Maxwell Donley M.B.A., Exec. VP of Operations & Strategy (Age 52, Pay $627.51k)
  • Mr. Stephen P. Robertson, Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 39, Pay $193.43k)
  • Mr. Massimiliano Colao, Chief Commercial Officer (Age 56, Pay $719.79k)
  • Dr. Glenn Schulman, Sr. VP of Corp. Communications & Investor Relations
  • Mr. Chris Hays, VP of Marketing
  • Mr. Fran Lynch, VP of Sales
  • Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C), Exec. VP of Research (Age 56)
  • Mr. Michael R. Martin, Chief Bus. Officer (Age 49)

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (4.74%), BlackRock Inc. (0.86%), Rock Springs Capital Management LP (0.61%), DG Capital Management LLC (0.46%), Blackcrane Capital LLC (0.39%) and FIL Ltd (0.37%). Company insiders that own Aurinia Pharmaceuticals stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Peter Greenleaf and Stephen P Robertson.
View institutional ownership trends for Aurinia Pharmaceuticals
.

Which major investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, D. E. Shaw & Co. Inc., Man Group plc, Allianz Asset Management GmbH, TD Asset Management Inc., Prosight Management LP, and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.
View insider buying and selling activity for Aurinia Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, DG Capital Management LLC, Blackcrane Capital LLC, FIL Ltd, DnB Asset Management AS, Barclays PLC, Gabelli Funds LLC, and InterOcean Capital Group LLC. Company insiders that have bought Aurinia Pharmaceuticals stock in the last two years include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Peter Greenleaf, and Stephen P Robertson.
View insider buying and selling activity for Aurinia Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $13.40.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals has a market capitalization of $1.72 billion and generates $50.12 million in revenue each year. The biotechnology company earns $-102,680,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

How many employees does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals employs 294 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Where are Aurinia Pharmaceuticals' headquarters?

Aurinia Pharmaceuticals is headquartered at 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]


This page was last updated on 6/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.